Arrowstreet Capital Limited Partnership Buys 1,013,456 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Arrowstreet Capital Limited Partnership grew its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 57.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,762,700 shares of the biotechnology company's stock after purchasing an additional 1,013,456 shares during the period. Arrowstreet Capital Limited Partnership owned about 1.17% of ADMA Biologics worth $47,380,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ADMA. GAMMA Investing LLC increased its holdings in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 967 shares in the last quarter. National Bank of Canada FI bought a new stake in shares of ADMA Biologics during the third quarter worth about $35,000. Mark Sheptoff Financial Planning LLC acquired a new position in shares of ADMA Biologics in the fourth quarter valued at approximately $35,000. Vision Financial Markets LLC bought a new position in ADMA Biologics in the 4th quarter valued at approximately $51,000. Finally, AlphaQuest LLC acquired a new stake in ADMA Biologics during the 4th quarter worth approximately $84,000. 75.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

Remove Ads

ADMA Biologics Trading Down 7.4 %

Shares of ADMA stock traded down $1.44 on Friday, hitting $18.01. The company had a trading volume of 3,763,503 shares, compared to its average volume of 3,536,652. ADMA Biologics, Inc. has a twelve month low of $5.90 and a twelve month high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market cap of $4.26 billion, a P/E ratio of 64.32 and a beta of 0.60. The stock's 50-day moving average is $17.45 and its two-hundred day moving average is $18.19.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.